Fundraising FoxAlexandria — 2019 Investments
10 investments dated 2019 · listed companies and verified rows first · show all
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementCity Hill VenturesSectoral Asset Management+3 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalArix BioscienceJMI Equity+3 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.
BiotechHealthtechNew York, US
Shoshana Shendelman(Executive Officer, Director)in
BoardLes Funtleyder(Director)
Board seatJoel Marcus· per SEC Form D · $20M raise · filed Nov 2019
Co-investorsEvolution VC PartnersVenrock Healthcare Capital Partners
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation Endeavors+6 more
.png)
Gencove provides direct-to-consumer genetic sequencing and polygenic risk scoring for health insights.
BiotechDigital HealthHealthtechNew York, US
Tomaz Berisa(Executive Officer, Director)inJoseph Pickrell(Executive Officer, Director)in
BoardSara Eshelman(Director)in
Co-investorsBread And Butter Ventures, LlcSpero VenturesVersion One VenturesBalaji SrinivasanBurst CapitalRefactor Capital+1 more
Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health.
AI & Machine LearningBiotechHealthtechLongevityBoston, US
Philip Strandwitz(Co-founder & Director, Chief Executive Officer)inKim Lewis(Co-founder, Director)Mike La Fleur(President, Co-founder, Director)Michael LaFleur(Executive Officer)
BoardJoan LaRovere(Director)inIain Chessell(Director)
Co-investorsAble PartnersAstanor VenturesBantam GroupDeep FutureHealthtech CapitaliSelect Fund+4 more
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+6 more
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersPivotal Life SciencesSofinnova VenturesPureTech HealthWellcome Trust
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundALTITUDE LIFE SCIENCE VENTURES+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.